Genexine, ToolGen Merger Collapses Amid Stock Drops, But Collaboration Still Planned

The planned merger between Genexine and ToolGen, which was poised to create a major Korean biotech entity, has collapsed amid recent generally weak investor sentiment over the sector. But the two sides will maintain their collaborations for new drug development going forward, with a focus on gene and cell therapies.

Wooden_Blocks
Genexine,ToolGen Fail To Cross Last Merger Hurdle • Source: Shutterstock

More from South Korea

More from Focus On Asia